NO20012214L - Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller - Google Patents

Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller

Info

Publication number
NO20012214L
NO20012214L NO20012214A NO20012214A NO20012214L NO 20012214 L NO20012214 L NO 20012214L NO 20012214 A NO20012214 A NO 20012214A NO 20012214 A NO20012214 A NO 20012214A NO 20012214 L NO20012214 L NO 20012214L
Authority
NO
Norway
Prior art keywords
sertoli cells
biological factor
creation
preparation
genetically modified
Prior art date
Application number
NO20012214A
Other languages
English (en)
Other versions
NO20012214D0 (no
Inventor
Shaun A Kirkpatrick
Original Assignee
Shaun A Kirkpatrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaun A Kirkpatrick filed Critical Shaun A Kirkpatrick
Publication of NO20012214D0 publication Critical patent/NO20012214D0/no
Publication of NO20012214L publication Critical patent/NO20012214L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Den foreliggende oppfinnelse tilveiebringer en fremgangsmåte for å frembringe til et individ en biologisk faktor eller et intermediat derav som omfatter innføring i individet sertoliceller som er genetisk endrede til å fremstille en biologisk faktor eller et intermediat derav. De genetisk endrede sertolicellene blir administrert i en mengde som er effektiv for å gi den ønskede effekten. I tillegg til å fremstille den biologiske faktoren eller intermediatet derav, danner de fremstilte sertolicellene også et immunologisk fordelaktig sete. Det tilveiebringes også vektorer som omfatter en promoter som fungerer i sertoliceller og er operabelt bundet til en kodende sekvens for en ønsker biologisk faktor. Det tilveiebringes også sertoliceller som omfatter slike vektorer og en farmasøytisk sammensetning som omfatter sertoliceller som er genetisk endret for å fremstille en biologisk faktor.
NO20012214A 1998-11-06 2001-05-04 Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller NO20012214L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10743898P 1998-11-06 1998-11-06
PCT/US1999/026072 WO2000027409A1 (en) 1998-11-06 1999-11-04 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells

Publications (2)

Publication Number Publication Date
NO20012214D0 NO20012214D0 (no) 2001-05-04
NO20012214L true NO20012214L (no) 2001-07-06

Family

ID=22316637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012214A NO20012214L (no) 1998-11-06 2001-05-04 Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller

Country Status (10)

Country Link
EP (1) EP1126858B1 (no)
JP (1) JP5323293B2 (no)
AT (1) ATE452643T1 (no)
AU (1) AU767763B2 (no)
CA (1) CA2349475C (no)
DE (1) DE69941849D1 (no)
DK (1) DK1126858T3 (no)
ES (1) ES2338076T3 (no)
NO (1) NO20012214L (no)
WO (1) WO2000027409A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
DE60128130T2 (de) * 2000-11-03 2007-12-27 Zymogenetics, Inc., Seattle Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169128T3 (es) * 1994-04-13 2002-07-01 Res Corp Technologies Inc Procedimientos para el tratamiento de enfermedades utilizando celulas de sertoli y aloinjertos o xenoinjertos.
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease

Also Published As

Publication number Publication date
JP2002529419A (ja) 2002-09-10
ES2338076T3 (es) 2010-05-03
DE69941849D1 (de) 2010-02-04
AU767763B2 (en) 2003-11-20
NO20012214D0 (no) 2001-05-04
CA2349475C (en) 2010-01-05
CA2349475A1 (en) 2000-05-18
AU1813200A (en) 2000-05-29
ATE452643T1 (de) 2010-01-15
EP1126858B1 (en) 2009-12-23
WO2000027409A1 (en) 2000-05-18
EP1126858A1 (en) 2001-08-29
EP1126858A4 (en) 2004-06-30
DK1126858T3 (da) 2010-03-01
JP5323293B2 (ja) 2013-10-23

Similar Documents

Publication Publication Date Title
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
PL322015A1 (en) Derivatives of hydroxylamine useful as compounds enhancing production of accompanying molecular protein and ethod of obtaining them
AU6331898A (en) Forskohlin for promoting lean body mass
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
IL206293A0 (en) Genetically engineered duckweed
GB2301363A (en) Human phosphodiesterase type ivc and its production and use
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
ATE410054T1 (de) Durch elektroporation vermittelter molekulartransfer in intakten pflanzen
ATE258933T1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
BR9707994A (pt) Adenovírus recombinantes defectivo composição farmacêutica utilização do adenovirus composição e processo de preparação de células t citotóxicas especificas de um antigene tumoral
NZ334568A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
NO20012214D0 (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
EP0684831A4 (en) ALLOGENIC VACCINE AND METHOD FOR SYNTHESIZING THE SAME.
MXPA03007002A (es) Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.
DE69920216D1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
DK0966532T3 (da) Biologisk materiale til behandling af et pattedyr ved antistofgenoverföring og farmaceutisk præparat indeholdende dette

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application